Orthopedic Biologics Supplier in Daytona Beach, Florida

Vendor qualification before the first order

Orthopedic groups and surgery centers generally run new tissue and biologics vendors through a short qualification step before placing a first order: confirming the supplier's recovery and processing description, requesting the certificate of analysis format, and reviewing how lot-level sterility testing and quarantine release are documented.

A medical director or designated purchasing lead typically signs off on the vendor file, and that file is kept alongside other supply agreements for audit purposes.

NPI-verified ordering accounts

Every Precision Biologics account is tied to a National Provider Identifier. Before an account is activated, the NPI is checked against the NPPES registry to confirm it belongs to a licensed physician or a clinic operating under physician supervision.

This verification step is separate from clinical decision-making: Precision Biologics does not advise on dosing, technique, or patient selection, and account verification does not constitute a determination about how any product may be used.

Receiving cryopreserved shipments in the Southeast

Cryopreserved Wharton's jelly and exosome products ship overnight on dry ice in validated containers. Practices in the Southeast region should confirm a staff member is available to receive and log shipments on the scheduled delivery day, since cold-chain integrity depends on prompt transfer to -80 degree C storage on arrival.

Lyophilized formats do not require this cold-chain step, which some practices factor into which product formats they keep on hand for scheduling flexibility.

Confirming licensure and Florida's regulatory posture

Each ordering account should independently confirm its own medical director's licensure status with the Florida Board of Medicine and consult legal counsel on how state and federal rules apply to its intended use of any product. Precision Biologics does not provide legal or clinical guidance.

Florida's SB 1768, effective July 1, 2025, permits licensed MD/DO physicians to use certain non-FDA-approved stem cell therapies in specific practice areas, including orthopedics, subject to informed consent and disclosure requirements. It does not change federal FDA regulation of any product, and a Florida license alone does not establish that a particular product or use is appropriate; practices should review the statute directly with counsel.

Precision Biologics supports new accounts by assembling the standard documentation set, including the lot release record, donor eligibility summary, and certificate of analysis, so a practice's compliance review can proceed without back-and-forth requests.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.